U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07771465) titled 'A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy' on July 20.
Brief Summary: Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Symptomatic Genetic D...